Table 1.
Demographics and clinical characteristics.
| Variable | Definitive therapy |
No definitive therapy |
P value |
|---|---|---|---|
| Total patients, n (%) | 115 (45) | 138 (55) | |
| Median age at initiation of ADT (IQR) | 68 (63–76) | 67.5 (62–75) | 0.81 |
| Race | |||
| Black/African American | 6 (5) | 21 (15) | 0.025 |
| Other | 96 (83) | 100 (72) | |
| Unknown | 13 (11) | 17 (12) | |
| Gleason score | |||
| Median, (IQR) | 7 (7–9) | 8 (7–9) | <0.0001 |
| Missing, n (%) | 9 (8) | 22 (16) | |
| ECOG Performance Status at initiation of ADT, n (%) | |||
| 0 | 62 (54) | 60 (44) | 0.25 |
| 1 | 23 (20) | 38 (28) | |
| 2 | 3 (3) | 9 (7) | |
| 3 | 1 (1) | 1 (1) | |
| Presence of visceral mets at dx, | |||
| n (%) | 6 (5) | 13 (9) | 0.18 |
| Missing, n (%) | 9 (8) | 15 (11) | |
| PSA at initiation of ADT | |||
| Median, (IQR) | 15 (6–44) | 75 (18–392) | <0.0001 |
| Missing, n (%) | 8 (7) | 3 (2) | |
| Testosterone at initiation of ADT | |||
| Median, (IQR) | 296 (173–458) | 213 (8–406) | 0.031 |
| Missing, n (%) | 41 (36) | 63 (55) | |
| PSA 6–7 mo after ADT | |||
| Median, (IQR) | 0.2 (0.1–1.1) | 1.1 (0.11–4.2) | 0.004 |
| Missing, n (%) | 49 (43) | 55 (48) | |
| Testosterone 6–7 m after ADT | |||
| Median, (IQR) | 7.5 (3–20) | 10 (3–20) | 0.57 |
| Missing, n (%) | 73 (64) | 103 (75) | |
| Type of DT received | |||
| Radical prostatectomy | 64 (56%) | ||
| Definitive radiation | 35 (30%) | ||
| Prostatectomy + radiation | 16 (14%) | ||
ADT = androgen deprivation therapy; DT = definitive therapy.